within Pharmacolibrary.Drugs.ATC.L;

model L01EX05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.69,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 160 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.11,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008833333333333334,
    Tlag           = 18.0,            
    Vdp             = 0.057,
    k12             = 6.0,
    k21             = 6.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Regorafenib is an orally active multi-kinase inhibitor that targets several protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. It is approved for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma in patients who have been previously treated with other therapies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in adult patients with advanced solid tumors in clinical studies, both male and female, typical population includes patients aged 40-70 years. The parameters are based on oral dosing.</p><h4>References</h4><ol><li><p>Fukudo, M, et al., &amp; Ueno, N (2021). Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. <i>Investigational new drugs</i> 39(5) 1422–1431. DOI:<a href=\"https://doi.org/10.1007/s10637-021-01115-4\">10.1007/s10637-021-01115-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33830408/\">https://pubmed.ncbi.nlm.nih.gov/33830408</a></p></li><li><p>Gerisch, M, et al., &amp; Lettieri, J (2018). Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. <i>Cancer chemotherapy and pharmacology</i> 81(1) 195–206. DOI:<a href=\"https://doi.org/10.1007/s00280-017-3480-9\">10.1007/s00280-017-3480-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29188322/\">https://pubmed.ncbi.nlm.nih.gov/29188322</a></p></li><li><p>Zopf, D, et al., &amp; Gerisch, M (2016). Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. <i>Cancer medicine</i> 5(11) 3176–3185. DOI:<a href=\"https://doi.org/10.1002/cam4.883\">10.1002/cam4.883</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27734608/\">https://pubmed.ncbi.nlm.nih.gov/27734608</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX05;
